Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04961307

Enrollment

Registered

2021-07-14

Start date

2019-07-05

Completion date

2021-12-30

Last updated

2021-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antitumor Drugs, Breast Cancer, Cardiotoxicity, Trastuzumab

Keywords

Cardiac safety, Antitumor drugs, Breast Cancer, Trastuzumab

Brief summary

By dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography and biomarker indicators And specificity, explore effective and specific early warning indicators, and provide technical support for the evaluation of the cardiac safety of anti-tumor drugs.

Detailed description

Thirty female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase), follow-up echocardiography and biomarkers at 1 month, 3 months and 6 months after chemotherapy.

Interventions

DRUGTrastuzumab

30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Inclusion criteria

* Patients with breast cancer (18-70 years old) * Patients who are planning to undergo trastuzumab for the first time

Exclusion criteria

* Organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy * liver and kidney failure * severe cerebrovascular disease * chronic obstructive pulmonary disease * rheumatic immune system disease * other tumors

Design outcomes

Primary

Measure	Time frame	Description
Time ending	6 months	180 days after chemotherapy

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026